300463.SZ SHZ
Maccura Biotechnology Co.Ltd
1W: +0.8%
1M: +3.0%
3M: +11.6%
YTD: -20.7%
1Y: -24.3%
3Y: -35.0%
5Y: -74.7%
¥9.53 ($1.42)
+0.20 (+2.14%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$2.5B
-12.0% ▼
5Y CAGR: -4.6%
Gross Profit
$1.4B
-9.0% ▼
5Y CAGR: -3.4%
Operating Income
$170M
-48.7% ▼
5Y CAGR: -24.6%
Net Income
$127M
-59.4% ▼
5Y CAGR: -24.7%
EPS (Diluted)
$0.21
-59.2% ▼
5Y CAGR: -26.0%
EBITDA
$582M
-7.1% ▼
5Y CAGR: -8.7%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $4.0B | $3.6B | $2.9B | $2.5B |
| YoY Growth | +14.9% | +7.5% | -9.4% | -19.7% | -12.0% |
| Cost of Revenue | $1.8B | $1.7B | $1.7B | $1.4B | $1.2B |
| Gross Profit | $1.9B | $2.2B | $1.9B | $1.5B | $1.4B |
| Gross Margin | 51.5% | 56.3% | 52.6% | 52.2% | 54.0% |
| R&D Expenses | $202M | $207M | $273M | $324M | $323M |
| SG&A Expenses | $637M | $756M | $750M | $806M | $790M |
| Operating Expenses | $918M | $1.0B | $1.1B | $1.2B | $1.2B |
| Operating Income | $990M | $1.2B | $817M | $331M | $170M |
| Operating Margin | 26.7% | 30.5% | 22.7% | 11.4% | 6.7% |
| Interest Expense | $70M | $61M | $36M | $34M | $23M |
| Income Before Tax | $970M | $1.2B | $789M | $305M | $125M |
| Tax Expense | $148M | $185M | $87M | $690K | $6M |
| Net Income | $794M | $957M | $708M | $313M | $127M |
| Net Margin | 21.4% | 24.0% | 19.6% | 10.8% | 5.0% |
| EPS (Diluted) | $1.42 | $1.72 | $1.17 | $0.51 | $0.21 |
| EBITDA | $1.2B | $1.5B | $1.1B | $627M | $582M |
| Shares Outstanding | 557M | 557M | 608M | 612M | 613M |